Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
06/03/2026 23:21
March 6 (Reuters) - Lisata Therapeutics Inc LSTA.O: LISATA THERAPEUTICS ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY KUVA LABS, INC. LISATA THERAPEUTICS INC - KUVA TO BUY LISATA FOR $5.00 PER SHARE IN CASH PLUS ONE CVR PER SHARE LISATA THERAPEUTICS INC - CVR ENTITLES ADDITIONAL $1.00 PER SHARE IF NDA FOR CERTEPETIDE IS FILED OR ACCEPTED LISATA THERAPEUTICS INC - BOARD UNANIMOUSLY APPROVES DEAL AND RECOMMENDS STOCKHOLDERS TENDER SHARES LISATA THERAPEUTICS INC - TO BE DELISTED FROM NASDAQ AND DEREGISTER AS REPORTING COMPANY AFTER DEAL CLOSE Source text: ID:nGNX3yMtNh Further company coverage: LSTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal